 This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid UDCA in patients with chronic hepatitis C in Japan. The primary objectives of this study are to verify the superiority of efficacy of UDCA 600 or 900mgday to that of 150mgday and the safety of UDCA treatment. 